Sherbrooke Park Advisers’s Amgen AMGN Stock Holding History

Sherbrooke Park Advisers’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,529	Closed	-$411K	–	451
2023 Q3	$411K	Buy	+1,529	New	+$382K	0.13%	280

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sherbrooke Park Advisers's AMGN Position: Q4 2023 in Review

Sherbrooke Park Advisers sold out of Amgen (AMGN) in Q4 2023, closing a stake of 1,529 shares — an estimated $411K sold.

Sherbrooke Park Advisers first reported a position in AMGN in Q3 2023 and held it in 1 quarter. The position peaked at $411K in Q3 2023. 2,715 funds tracked by Wall St. Rank hold AMGN as of Q4 2023.

Sherbrooke Park Advisers reported no remaining Amgen position as of Q4 2023 after selling out during the quarter.
Sherbrooke Park Advisers sold 1,529 Amgen shares in Q4 2023, an estimated $411K.
Sherbrooke Park Advisers first reported a position in Amgen in Q3 2023 and held it in 1 quarter.
Sherbrooke Park Advisers's Amgen position peaked at $411K in Q3 2023.
2,715 funds tracked by Wall St. Rank held Amgen as of Q4 2023.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.